Trial Profile
A PHASE 1/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs PF 06760805 (Primary)
- Indications Streptococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 18 Mar 2024 Status changed from active, no longer recruiting to completed.
- 13 Mar 2024 Planned End Date changed from 10 Mar 2024 to 4 Mar 2024.
- 20 Jul 2023 Results (n=494) assessing safety of GBS6 vaccine in non-pregnant and pregnant females presented in the New England Journal of Medicine